Table 1.
T. cruzi epitopes recognized by T cells from Chagas disease patients.
| aEpitope | bID | cAntigen Name | T cell/HLA Restriction | dRecognition by T cells in Mouse Models | Reference |
|---|---|---|---|---|---|
| VLAKDGTEV IAGGVMAVV FVNHDFTVV LLLLGLWGL LLGLWGLTGL |
ASP-150
ASP-171 ASP-1508 ASP-1666 ASP-1668 |
Surface protein 1/trans-sialidase, putative/amastigote surface protein-1 (ASP-1) | CD8+/ HLA-A*02:01 |
Yes (A2.1/Kb Tg mice) |
(32, 36) |
| WVFPESISPV FVNHRFTLV |
ASP-2302
ASP-2551 (TSA2-37) |
Surface protein 2/trans-sialidase, putative, Group II/amastigote surface protien-1 (ASP-2) | CD8+/ HLA-A*02:01 |
Yes (A2.1/Kb Tg mice) |
(30, 32, 33, 36) |
| KLFPEVIDL FVDYNFTIV VLLPSLFLL VLLPSLFLLL |
TSA-189
TSA-1514 TSA-1818-826 TSA-1818-827 |
Trypomastigote surface glycoprotein/trans-sialidase, putative/trypomastigote surface antigen-1 (TSA-1) | CD8+/ HLA-A*02:01 |
Yes (A2.1/Kb Tg mice; HHD Tg mice) |
(32, 36, 37) |
| LLGLWVFAAL GLLPSLLLLL RLLPSLLLLL LLGLWGTAAL FLSHDFTLV SLSHYFTLV FLSHNFTLV FVNYDFALV FANCNFTLV FANHDFTLV FVSCDFTIV FANHKFTLV FANNKFTLV FANYKFTLV FVNYNFTLV FANHNFTLV FVDYNFSLV FANYNFTLV IANYNFTLV FANNEFTLV FVNYDFTIV ELLRPTTLV DVSRPTAVV |
TSA2-2 TSA2-3 TSA2-3.2 TSA2-13 TSA2-24 TSA2-26 TSA2-27 TSA2-28 TSA2-32 TSA2-34 TSA2-35 TSA2-38 TSA2-43 TSA2-44 TSA2-45 TSA2-46 TSA2-47 TSA2-48 TSA2-48.3 TSA2-49 TSA2-50 TSA2-52 TSA2-66 |
Trans-sialidase, putative | CD8+/ HLA-A*02:01 |
Yes (A2.1/Kb Tg mice) |
(30, 33) |
| VTDNNRSFY LWLTDNTHI LLLGLWGFA YNFTLVATV FTSAVLLLL MLVTLPVYS NVMLVTLPV FVSPSLVSA ALSSSLGNV HLFYSAVLL FLYNRPLNS HNFTLVASV LLLLVVMMCC TSAVLLLLVV SIPTAGLVAV FQGAWAEWPV RVLLLLLLGL MLSRVAAVK FTLVATVSI FTLVASVTI AVAEAQCKK VALMLQGNK LVTLPVYSK DVAASSLLY ITATIEGRK IYMLVGKYS GVIAAFAEGH |
Trans-sialidase, putative | CD8+/ HLA-A1 HLA-A2 HLA-A2 HLA-A2 HLA-A2 HLA-A2 HLA-A2 HLA-A2 HLA-A2 HLA-A2 HLA-A2 HLA-A2 HLA-A2 HLA-A2 HLA-A2 HLA-A2 HLA-A2 HLA-A3 HLA-A3 HLA-A3 HLA-A3 HLA-A3 HLA-A3 HLA-A3 HLA-A3 HLA-A3 HLA-A3 |
Not tested | (30) | |
| FTSAVLLLV VMMSCSSEA SMNATLVQA RLLSPTTIV KVVSLVILA AASTLLYATV TLLYATVEV KLYCSYEVA WLSDCGEAL KTWADEYLCV FTLVAPVSI IILNGSLLTL QMDYSNGLFV GLLLLGLWGT LLLGLWGTA |
FL 6–14
FL 16–24 FL 47–55 FL 120–128 FL 236–244 FL 377–386 FL 380–388 FL 401–409 FL457– 465 FL 480–489 FL 534–542 FL 581–590 FL 610–619 FL 990–999 FL 992–1000 |
Flagellum-associated protein/trans-sialidase, putative, Group III/FL-160-1 | CD8+/ HLA-A*02:01 |
Not tested | (31) |
| ALSLAAVLV ALSLAAVLVV VVMACLVPAA VMACLVPAA SVFRENLFL GLMNNAFEWI LMNNAFEWI LMNNAFEWIV WIIKNSWTA VTLPTGQCL LLTTSGVSA |
CZ 7–15
CZ 7–16 CZ 15–24 CZ16–24 CZ60–68 CZ 188–197 CZ 189–197 CZ 189–198 CZ 300–308 CZ 378–386 CZ 386–394 |
Cysteine peptidase, putative, cathepsin L-like protein, putative | CD8+/ HLA-A*02:01 |
Not tested | (31) |
| RQRRYQPYHSRHRRL | Cruzipain/cysteine peptidase, putative/major cysteine protease | CD8+/ HLA-A*31:01 |
Not tested | (38) | |
| AVPEVTDVTL KLEKIEDEL RLYKTLGQL |
PFR219–28
PFR2156–163 PFR2449–457 |
Major paraflagellar rod protein/paraflagellar rod protein 2 (PFR2) | CD8+/ HLA-A*02:01 |
Yes (A2.1/Kb Tg mice) |
(39, 40) |
|
FVSCCGELTV
DIIEQMKGV GVSGVINAL |
PFR3428–436
PFR3475–482 PFR3481–489 |
Paraflagellar rod component, putative | CD8+/ HLA-A*02:01 |
Yes (A2.1/Kb Tg mice) |
(39, 40) |
| TLEEFSAKL | KMP-114−12
(KP-1 or TcTLE) |
Kinetoplastid membrane protein-11 (KMP-11) | CD8+/ HLA-A1 (A*0101, A*3201) HLA-A2 (A*0201, A*0205, A*0222, A*0226, A*0259, A*0287, A*6802) HLA-A24 (A*2402, A*2301) |
Yes (A2.1/Kb Tg mice) |
(40–46) |
| TLLTIDGGI TLQPVERVL |
HSP70210-8
HSP70316-24 |
Heat shock protein-70 (HSP-70) | CD8+/ HLA-A*02:01 |
Yes (A2.1/Kb Tg mice) |
(47) |
| AAAGDKLSL TVFDASRSTV ALRNLRVFL ALQVTNHRYL |
TcCA-2273-281
TcCA-2442-451 TcCA-2607-615 TcCA-2657-666 |
Surface antigen 2 (CA-2)/TcCA-2 |
CD8+/ HLA-A*02:01 |
Not tested | (40, 48) |
| KPPPFGQAAAGDKPS KPSPFGQAAAGDKPP KPSPFGQAAAGGKPP KPPPFGQAAAGDKPP KPPPFGQAAEGDKPP KPPPFGQAAAADKPS KPSLFGQAAAGDKLS KLSLFGQAAAGDKPP KPPPFGQAAAGDKPA KPAPFGQAAEGDKPP |
S15.1 S15.2 S15.3 S15.4 S15.5 S15.6 S15.7 S15.8 S15.9 S15.10 |
B13 antigen Putative, surface antigen-2 (TcCA-2) |
CD4+/HLA-DQA1*0501/ DQB1*0301 (HLA-DQ7) |
Not tested | (49–51) |
| SADNTNSGAGGGLSSKAFEWIVQENNGAVYTED | Cruzipain, cysteine peptidase | CD4+/ HLA-class II |
Not tested | (52) | |
| VECQWFLAGHPLTNLS | TcCZp1 | Cruzipain, cysteine peptidase, putative, cysteine peptidase, clan CA, family C1, cathepsin L-like, putative | CD4+/ HLA-class II |
Not tested | (38) |
| ENQLYHFANYKFTLV | TcTSp1 | Putative trans-sialidase, Group V | CD4+/ HLA-class II |
Yes (A2.1/Kb Tg mice) |
(38) |
| TVPYHFANSKFTLVA | TcTSp2 | Putative trans-sialidase, Group III/Flagellum-associated protein FL-160-2 | CD4+/ HLA-class II |
Not tested | (38) |
| MLSLVAAVKAPRTHN | TcTSp3 | Putative trans-sialidase, Group V | CD4+/ HLA-class II |
Not tested | (38) |
| GVVMEDGTLVFPLMA | TcTSp4 | Putative trans-sialidase, Group II | CD4+/ HLA-class II |
Not tested | (38) |
| HRFTLVATVTIHQVPK | TcTSp5 | ASP-2/trans-sialidase, putative, Group II | CD4+/ HLA-class II |
Not tested | (38) |
a
Underlined sequences are evaluated in more than one publication referenced.
b
ID from publication.
c
Antigen name from NCBI database and the publication referenced.
d
Epitope recognition by T cells from a mouse model besides T cells from patients. Not tested refers to those peptides which are not evaluated in mouse models in publications referenced. HHD transgenic (Tg) mice express a chimeric HLA-A2 molecule consisting of human β2-microglubulin and human HLA-A2.1 α1 and α2 domains fused to the α3, transmembrane and cytoplasmatic domains of the mouse H2-D.